This approval is based on the Phase 3 CodeBreaK 300 study, which showed that this drug combination significantly improved progression-free survival (how long patients lived without their cancer ...

The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, 2025.

Issued on behalf of Oncolytics Biotech Inc. At the ASCO GI event, Oncolytics shared that in relapsed anal cancer, 4 out of 12 evaluable patients achieved a partial response for a response rate of ...

Issued on behalf of Oncolytics Biotech Inc. At the ASCO GI event, Oncolytics shared that in relapsed anal cancer, 4 out of 12 evaluable patients achieved a partial response for a response rate of 33%, ...